| Alicia Schumacher, AANPCP | |
|
520 N 32nd Ave, Wausau, WI 54401-4701 | |
| (715) 847-2424 | |
| Not Available |
| Full Name | Alicia Schumacher |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 520 N 32nd Ave, Wausau, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013264571 | NPI | - | NPPES |
| 1013264571 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 4913-33 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Flambeau Hospital | Park falls, WI | Hospital |
| Marshfield Medical Center | Marshfield, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mchs Hospitals Inc | 5698071173 | 1049 |
| Flambeau Hospital, Inc. | 9032029871 | 31 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
| Entity Name | Ascension Medical Group-fox Valley Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730126392 PECOS PAC ID: 0244142420 Enrollment ID: O20031105000351 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
| Entity Name | Marshfield Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
| Entity Name | Aspirus Wausau Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922321140 PECOS PAC ID: 6406757442 Enrollment ID: O20040114000297 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
| Entity Name | Fox Valley Hematology & Oncology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407868334 PECOS PAC ID: 6901709633 Enrollment ID: O20040130000043 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alicia Schumacher, AANPCP 2200 Westwood Dr, Wausau, WI 54401-7806 Ph: (715) 387-5511 | Alicia Schumacher, AANPCP 520 N 32nd Ave, Wausau, WI 54401-4701 Ph: (715) 847-2424 |
News Archive
Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.
An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine.
Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.
NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has raised $17.5 million in a Series B financing round. The financing was led by a new investor, Care Capital, LLC, with participation from existing venture investor Index Ventures.
Lymphedema, a chronic swelling condition common in breast cancer survivors, affects three million people in the U.S. In the past, most people believed that exercise might induce or worsen lymphedema. After reviewing the literature, University of Missouri researchers say the benefits of exercise outweigh the risks for breast cancer survivors and patients with lymphedema.
› Verified 8 days ago
Ms. Jacquelyn Forbes Kearns, MS,ARNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2727 Plaza Dr, Wausau, WI 54401 Phone: 715-847-3000 | |
Kyla P Teresinski, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 510 N 17th Ave Ste C, Wausau, WI 54401 Phone: 715-849-5333 Fax: 715-849-4083 | |
Marietta S Kern, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 218 N 28th Ave, Wausau, WI 54401 Phone: 715-847-2866 | |
Bradley A Mueller, APNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 225000 Hummingbird Rd Ste 100, Wausau, WI 54401 Phone: 715-359-6442 Fax: 715-393-0390 | |
Gina E Ramthun, APNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1901 Westwood Center Blvd, Wausau, WI 54401 Phone: 715-355-9424 | |
Tiffany Pluger, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2400 Marshall St Ste A, Wausau, WI 54403 Phone: 715-848-4356 Fax: 715-845-5398 |